Vuity FDA Approval History
Last updated by Judith Stewart, BPharm on Nov 10, 2021.
FDA Approved: Yes (First approved October 28, 2021)
Brand name: Vuity
Generic name: pilocarpine hydrochloride
Dosage form: Ophthalmic Solution
Company: AbbVie Inc.
Treatment for: Presbyopia
Vuity (pilocarpine hydrochloride) is an optimized ophthalmic solution formulation of the approved cholinergic muscarinic receptor agonist pilocarpine indicated for the treatment of presbyopia (age-related blurry near vision).
- Presbyopia is caused when the lens of the eye can't change shape to focus light correctly on the retina, making it difficult to focus on near objects.
- Vuity works by activating the muscarinic receptors to contract the iris sphincter muscle in the eye. This constricts the pupil, while still maintaining some pupillary response to light.
- Vuity is administered by instilling one drop into each eye once daily. It works in as early as 15 minutes and lasts up to 6 hours to improve near and intermediate vision without impacting distance vision.
- Patients using Vuity should be aware of undertaking hazardous activities in poor light such as night driving. Rare cases of retinal detachment have been reported in patients using other miotics, so patients using Vuity are advised to seek immediate medical care if they experience sudden onset of vision loss.
- Common adverse reactions include headache and conjunctival hyperemia.
Development timeline for Vuity
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
